Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma

Inclusion Criteria: * 18 years of age or older * Biopsy proven classical Hodgkin lymphoma. Classical Hodgkin lymphoma includes the subtypes of nodular sclerosis, mixed cellularity, lymphocyte rich, lymphocyte depleted, and classical Hodgkin lymphoma unspecified * Advanced stage (Stage III or IV) disease * Measurable disease on cross sectional imaging * ECOG Performance Status 0-2 * Adequate blood counts and organ function Exclusion Criteria: * Pregnant or lactating women * Laboratory Parameters as outlined in the protocol * LV ejection fraction lower than normal as assessed by echocardiogram or MUGA scan * DLCO less than 60% as measured by pulmonary function tests * Prior history of another malignancy (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease free for over one year * Current or recent (within 4 weeks of the first infusion of this study) participation in an experimental drug study * Life expectancy of less than 12 weeks * Inability to comply with study procedures * Inability to give informed consent * Inadequately controlled hypertension * Any prior history of hypertensive crisis or hypertensive encephalopathy * NYHA Grade II or greater congestive heart failure * History of myocardial infarction or unstable angina within 6 months prior to study enrollment * History of stroke or transient ischemic attack within 6 months prior to study enrollment * Known CNS involvement of Hodgkin lymphoma * Significant vascular disease * Symptomatic peripheral vascular disease * Evidence of bleeding diatheses or coagulopathy * Use of daily anticoagulant medications including warfarin, heparins, or aspirin \>325mg daily * Major surgical procedure or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days of study enrollment * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment * Serious, non-healing wound, ulcer, or bone fracture * Proteinuria at screening * Known hypersensitivity to any component of bevacizumab * Pregnant or lactating